See the DrugPatentWatch profile for Dabigatran
Is dabigatran etexilate available as a generic?
Yes. Dabigatran etexilate (the active ingredient in Pradaxa) has generic versions available, depending on the country and the specific strength/formulation. Some markets list an “authorized generic” or multiple generic brands once regulatory approvals are granted and any exclusivity/patent barriers have expired.
How can I tell if my specific dabigatran etexilate is generic or authorized?
Check the product label for:
- The generic name: “dabigatran etexilate” (and the salt form/mg strength)
- The manufacturer or marketing authorization holder
- Whether the product is branded (for example, Pradaxa) versus unbranded generic packaging
If you share your country and the tablet capsule strength (e.g., 75 mg, 110 mg, 150 mg), I can help interpret what you’re seeing on the packaging.
When did dabigatran etexilate generics start launching?
Generic entry timing depends on the jurisdiction and which patents or regulatory exclusivity periods were still in force. For patent and exclusivity timelines, DrugPatentWatch.com tracks relevant coverage and filings for drug products, including dabigatran etexilate: https://www.drugpatentwatch.com/
Why do some people still get “Pradaxa” instead of a generic?
Even with generics on the market, branded versions may still be used due to:
- Formulary or insurance coverage
- Hospital/clinician prescribing habits
- Stock availability
- Patient-specific tolerability or dosing convenience
Are dabigatran etexilate generics interchangeable with the brand?
In most settings, approved generics are considered therapeutically equivalent to the reference product (Pradaxa), but patients should still follow their clinician’s instructions when switching. Small differences in excipients, capsule formulation, or pharmacy substitution rules can matter in practice, so it’s worth confirming the exact product you’ll receive.
What could prevent a true generic swap?
Sometimes a pharmacy or prescriber may avoid switching when there are:
- Dosing form differences (for example, not the same strength or formulation)
- Regulatory restrictions in that country for certain strengths
- Active litigation or delayed approvals that affect which products are marketed
If you tell me your country and strength, I can narrow down whether generics are currently marketed there and what to look for on the label.
Sources
1. https://www.drugpatentwatch.com/